Tamiflu (Oseltamivir Phosphate) Market Size to Exceed US$ 978.6 Mn by 2032

The Tamiflu (Oseltamivir Phosphate) Market, estimated at US$ 889.2 Mn in 2025,001.6, is expected to exhibit a CAGR of 1.2% and reach US$ 978.6 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

The following is the treatment regimen which is followed for the treatment of influenza A, influenza B, and others. For instance, according to the Center for Disease Control and Prevention (CDC), the below is the treatment regimen mentioned in detail for the treatment of influenza

• Adults and adolescents which are 13 years and older, oseltamivir phosphate should be administered 71,001.6 mg twice daily for 1,001.6 days
• In case of pediatric patients 1 to 12 years of age, based on weight, the oseltamivir phosphate should be administered twice daily for 1,001.6 days. Moreover, pediatric patients who are 2 weeks to less than 1 year of age, oseltamivir phosphate should be administered 3 mg/kg twice daily for 1,001.6 days
• In case of renally impaired adult patients, (creatinine clearance >30-60 mL/min, the dose of oseltamivir phosphate is reduced to 30 mg twice daily for 1,001.6 days. Moreover, in case of renally impaired adult patients (creatinine clearance >10-30 mL/min), the dose of oseltamivir phosphate is reduced to 30 mg once daily for 1,001.6 days
• In case of End-Stage Renal Disease (ESRD) patients on hemodialysis, the dose of oseltamivir phosphate is reduced to 30 mg immediately and then 30 mg after every hemodialysis cycle. The treatment duration does not to exceed more than 1,001.6 days

Global Tamiflu (Oseltamivir Phosphate) Market– Impact of Coronavirus (COVID-19) Pandemic

The coronavirus disease (COVID-19) pandemic is expected to hamper growth of the global Tamiflu (oseltamivir phosphate) market over the forecast period. The coronavirus cases are not increasing exponentially across the globe. For instance, according to the World Health Organization, as of December 18, 2025, globally, 649 million confirmed cases of COVID-19 and 6.6 million deaths due to COVID-19 were reported.

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdowns in several regions. Private healthcare is one such sector that has been significantly impacted by the COVID-19 pandemic.

Global Tamiflu (Oseltamivir Phosphate) Market: Key Developments

In December 2025, Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company, a part of Blue Cross Association, have added the oseltamivir phosphate (capsule 30 mg, 41,001.6 mg, 71,001.6 mg) and oral suspension and TAMIFLU oral capsule (30 mg, 41,001.6 mg and 71,001.6 mg) & oral suspension in their plan list. Oseltamivir phosphate is included in Tier 1 or 1b, while Tamiflu is included in Tier 3 of the plan.  Tier 1 or 1b mean drugs with a low cost share and Tier 3 means Drugs with a higher cost share than Tier 2.

Browse 29 Market Data Tables and 22 Figures spread through 180 Pages and in-depth TOC on “by Drug Type (Branded and Generic), by Dosage Form (Capsules and Suspension), by Indication (Influenza A, Influenza B, and Swine Flu (H1N1 Influenza A)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/tamiflu-oseltamivir-phosphate-market-5489

Key Takeaways of the Global Tamiflu (Oseltamivir Phosphate) Market:

• The global Tamiflu (oseltamivir phosphate) market is expected to exhibit a CAGR of 1.2% during the forecast period. Increasing prevalence of swine flu is expected to drive the growth of the indication segment, over the forecast period. For instance, according to the article published in the National Center for Biotechnology Information (NCBI): November 2025, in India, there was a 11,001.6 fold increase in the number of swine flu cases as compared to the 2025 year. i.e. there were 11,41,001.60 cases in reported in 2025, while in the year 2025, there were only 778 cases of swine flu reported.
• In terms of dosage form, capsule sub-segment is estimated to hold a dominant position in the global Tamiflu (oseltamivir phosphate) market over the forecast period, owing to increasing demand for oseltamivir capsules for the treatment of influenza. For instance, in July 2025, the Federal Bureau of Investigation (FBI) was seeking suppliers for the anti-viral therapeutic Tamiflu to support Pandemic Flu Preparedness Stockpile. The FBI has planned to stock approximately 3,300 does of Tamiflu 71,001.6 mg capsules (in containers of 10 caps per bottle) each year and in order to meet its stockpile requirements, which will be rotated on continuous use and expiring medications
• Among regions, North America, is expected to be the most dominant region in the global Tamiflu (oseltamivir phosphate) market, owing to increasing awareness campaign for the prevention of influenza among the U.S. population. For instance, according to the Center for Disease Control and Prevention (CDC), 2025, there was an awareness campaign orgfanized by CDC, which increased awareness regarding the development of healthy habits for protecting the patients against seasonal flu and its serious complications, among the population.
• Major players operating in the global Tamiflu (oseltamivir phosphate) market include Hoffmann-La Roche Ltd., NATCO Pharma Limited, Teva Pharmaceutical Industries Ltd., LUPIN Limited, Amneal Pharmaceuticals LLC, Zydus Cadila, Sun Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, Mylan N.V., and Hetero Group.